• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对接受A型肉毒杆菌毒素治疗的膀胱过度活动症患者的尿动力学和逼尿肌收缩性变量进行评估:膀胱排空不全是否可预测?

Assessment of urodynamic and detrusor contractility variables in patients with overactive bladder syndrome treated with botulinum toxin-A: is incomplete bladder emptying predictable?

作者信息

Sahai Arun, Sangster Philippa, Kalsi Vinay, Khan Mohammad S, Fowler Clare J, Dasgupta Prokar

机构信息

Department of Urology, Guy's Hospital & KCL School of Medicine, London, UK.

出版信息

BJU Int. 2009 Mar;103(5):630-4. doi: 10.1111/j.1464-410X.2008.08076.x. Epub 2008 Oct 16.

DOI:10.1111/j.1464-410X.2008.08076.x
PMID:18990156
Abstract

OBJECTIVE

To assess whether incomplete bladder emptying and the need for clean intermittent self-catheterization (CISC) is predictable, by analysing urodynamic and detrusor contractility variables in patients treated with botulinum toxin-A (BTX-A) for refractory idiopathic detrusor overactivity (IDO).

PATIENTS AND METHODS

Sixty-seven patients (mean age 50.3) with IDO, from two centres, had bladder injections of 200 U BTX-A. Patients with difficulty in emptying their bladder and/or persistent overactive bladder symptoms, with postvoid residual volumes (PVR) of >150 mL after treatment were started on CISC. Urodynamics were conducted at baseline, 4 and 12-16 weeks after injection with BTX-A. Detrusor contractility was assessed using the projected isovolumetric pressure (PIP1) in women and bladder contractility index (BCI) in men.

RESULTS

There were improvements in the mean maximum cystometric capacity, bladder compliance and maximum detrusor pressures during filling cystometry after BTX-A injections. The PVR was significantly increased at 4 but not at 12 weeks. Nineteen patients required CISC and when compared with those not needing CISC their pretreatment maximum flow rate (15 vs 22 mL/s, P = 0.003), PIP1 (43 vs 58, P = 0.02) and BCI (113 vs 180, P = 0.001) were lower. Receiver operator characteristic curve analysis suggested that a PIP1 of < or =50 in women (sensitivity 0.83; specificity 0.70; area under the curve 0.822) and BCI < or =120 (sensitivity 0.7; specificity 0.79; area 0.879) might predict the need for CISC.

CONCLUSION

The maximum flow rate, PIP1 and BCI were significantly lower in patients who required CISC after BTX-A treatment than in those who did not. A PIP1 of < or =50 in women and a BCI of < or =120 might be predictive of a need for CISC in this setting, and might help when counselling patients.

摘要

目的

通过分析接受肉毒杆菌毒素A(BTX-A)治疗难治性特发性逼尿肌过度活动症(IDO)患者的尿动力学和逼尿肌收缩性变量,评估膀胱排空不全及清洁间歇性自我导尿(CISC)需求是否具有可预测性。

患者与方法

来自两个中心的67例IDO患者(平均年龄50.3岁)接受了200 U BTX-A膀胱注射。膀胱排空困难和/或膀胱过度活动症状持续存在、治疗后残余尿量(PVR)>150 mL的患者开始进行CISC。在基线、注射BTX-A后4周和12 - 16周进行尿动力学检查。使用女性的预计等容压力(PIP1)和男性的膀胱收缩指数(BCI)评估逼尿肌收缩性。

结果

BTX-A注射后,平均最大膀胱测压容量、膀胱顺应性和充盈期膀胱测压时的最大逼尿肌压力均有改善。PVR在4周时显著增加,但在12周时未增加。19例患者需要CISC,与不需要CISC的患者相比,他们治疗前的最大尿流率(15 vs 22 mL/s,P = 0.003)、PIP1(43 vs 58,P = 0.02)和BCI(113 vs 180,P = 0.001)较低。受试者工作特征曲线分析表明,女性PIP1≤50(敏感性0.83;特异性0.70;曲线下面积0.822)和BCI≤120(敏感性0.7;特异性0.79;面积0.879)可能预测CISC需求。

结论

BTX-A治疗后需要CISC的患者,其最大尿流率、PIP1和BCI显著低于不需要CISC的患者。女性PIP1≤50和男性BCI≤120可能预测在这种情况下对CISC的需求,并可能有助于为患者提供咨询。

相似文献

1
Assessment of urodynamic and detrusor contractility variables in patients with overactive bladder syndrome treated with botulinum toxin-A: is incomplete bladder emptying predictable?对接受A型肉毒杆菌毒素治疗的膀胱过度活动症患者的尿动力学和逼尿肌收缩性变量进行评估:膀胱排空不全是否可预测?
BJU Int. 2009 Mar;103(5):630-4. doi: 10.1111/j.1464-410X.2008.08076.x. Epub 2008 Oct 16.
2
Urodynamic assessment of poor responders after botulinum toxin-A treatment for overactive bladder.A型肉毒杆菌毒素治疗膀胱过度活动症后反应不佳者的尿动力学评估
Urology. 2008 Mar;71(3):455-9. doi: 10.1016/j.urology.2007.11.039.
3
Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy.A型肉毒杆菌毒素治疗帕金森病和多系统萎缩患者的膀胱过度活动症及逼尿肌过度活动
J Urol. 2009 Oct;182(4):1453-7. doi: 10.1016/j.juro.2009.06.023. Epub 2009 Aug 15.
4
Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra.110例患者膀胱或尿道注射A型肉毒杆菌毒素的单机构经验。
Urology. 2005 Jan;65(1):37-41. doi: 10.1016/j.urology.2004.08.016.
5
Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents.A型肉毒毒素注射治疗抗胆碱能药物难治性逼尿肌过度活动有效性的尿动力学证据。
Urology. 2004 May;63(5):868-72. doi: 10.1016/j.urology.2003.12.007.
6
Improvement in quality of life after botulinum toxin-A injections for idiopathic detrusor overactivity: results from a randomized double-blind placebo-controlled trial.肉毒杆菌毒素A注射治疗特发性逼尿肌过度活动后生活质量的改善:一项随机双盲安慰剂对照试验的结果
BJU Int. 2009 Jun;103(11):1509-15. doi: 10.1111/j.1464-410X.2009.08402.x. Epub 2009 Apr 15.
7
Repeated injections of botulinum toxin-A for idiopathic detrusor overactivity.重复注射肉毒杆菌毒素 A 治疗特发性逼尿肌过度活动症。
Urology. 2010 Mar;75(3):552-8. doi: 10.1016/j.urology.2009.05.097. Epub 2009 Dec 29.
8
Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial.A型肉毒杆菌毒素治疗特发性逼尿肌过度活动症的疗效:一项单中心、随机、双盲、安慰剂对照试验的结果
J Urol. 2007 Jun;177(6):2231-6. doi: 10.1016/j.juro.2007.01.130.
9
Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics.对100例抗胆碱能药物难治性特发性膀胱过度活动症患者进行肉毒杆菌A毒素膀胱逼尿肌注射治疗的经验。
J Urol. 2006 Jul;176(1):177-85. doi: 10.1016/S0022-5347(06)00590-8.
10
Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: objective outcome and patient satisfaction.肉毒杆菌A毒素注射逼尿肌和括约肌治疗膀胱过度活动症:客观结果与患者满意度
Eur Urol. 2005 Dec;48(6):984-90; discussion 990. doi: 10.1016/j.eururo.2005.06.021. Epub 2005 Jul 18.

引用本文的文献

1
Evaluation of the effect of 100U of Onabotulinum toxin A on detrusor contractility in women with idiopathic OAB: A multicentre prospective study.评价 100U 肉毒毒素 A 对特发性 OAB 患者逼尿肌收缩力的影响:一项多中心前瞻性研究。
Neurourol Urodyn. 2022 Jan;41(1):306-312. doi: 10.1002/nau.24820. Epub 2021 Oct 19.
2
Using Botulinum Toxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome-Possible Pathomechanisms and Practical Issues.采用肉毒杆菌毒素 A 治疗间质性膀胱炎/膀胱疼痛综合征的可能发病机制和实际问题。
Toxins (Basel). 2019 Nov 4;11(11):641. doi: 10.3390/toxins11110641.
3
Efficacy of botulinum toxin type A 100 Units versus 200 units for treatment of refractory idiopathic overactive bladder.
A型肉毒杆菌毒素100单位与200单位治疗难治性特发性膀胱过度活动症的疗效比较
Int Braz J Urol. 2015 Nov-Dec;41(6):1132-40. doi: 10.1590/S1677-5538.IBJU.2014.0221.
4
Botulinum toxin-A for the treatment of overactive bladder: UK contributions.用于治疗膀胱过度活动症的A型肉毒杆菌毒素:英国的贡献。
J Clin Urol. 2013 Mar;6(2):77-83. doi: 10.1177/2051415812473096.
5
Urinary retention rates after intravesical onabotulinumtoxinA injection for idiopathic overactive bladder in clinical practice and predictors of this outcome.临床实践中膀胱内注射A型肉毒杆菌毒素治疗特发性膀胱过度活动症后的尿潴留发生率及该结果的预测因素。
Neurourol Urodyn. 2015 Sep;34(7):675-8. doi: 10.1002/nau.22642. Epub 2014 Jun 29.
6
Repeated botulinum toxin type A (Dysport) injections for women with intractable detrusor overactivity: a prospective outcome study.重复注射A型肉毒杆菌毒素(Dysport)治疗难治性逼尿肌过度活动症女性:一项前瞻性结局研究。
Int Urogynecol J. 2014 May;25(5):601-5. doi: 10.1007/s00192-013-2228-2. Epub 2013 Oct 17.
7
Novel biomarkers for overactive bladder.用于治疗膀胱过度活动症的新型生物标志物。
Nat Rev Urol. 2011 Mar;8(3):139-45. doi: 10.1038/nrurol.2011.7. Epub 2011 Feb 15.
8
Intravesical botulinum toxin for lower urinary tract dysfunction.膀胱内注射肉毒杆菌毒素治疗下尿路功能障碍。
F1000 Med Rep. 2010 Jan 27;2:6. doi: 10.3410/M2-6.
9
Intravesical instillation of botulinum toxin A: an in vivo murine study and pilot clinical trial.膀胱内注射肉毒毒素 A:一项体内小鼠研究和初步临床试验。
Int Urol Nephrol. 2011 Jun;43(2):337-43. doi: 10.1007/s11255-010-9790-z. Epub 2010 Jun 20.